Valneva And Pfizer Announced Further Immunogenicity And Safety Data From VLA15-221 Phase 2 Study Following A Second Booster Vaccination Of Their Lyme Disease Vaccine Candidate, VLA15, Given One Year After Receiving The First Booster Dose
Portfolio Pulse from Benzinga Newsdesk
Valneva and Pfizer have announced new data from their Phase 2 study of the Lyme disease vaccine candidate, VLA15. The study shows that the immune response and safety profile after a second booster dose are consistent with previous results, supporting the benefit of booster vaccinations.
September 03, 2024 | 9:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer, in collaboration with Valneva, has reported consistent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15, after a second booster dose. This supports the potential for seasonal booster vaccinations.
The consistent immunogenicity and safety data for VLA15 after a second booster dose is positive for Pfizer, as it supports the vaccine's potential for seasonal use. This could lead to future regulatory approvals and market opportunities.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Valneva, in partnership with Pfizer, has announced positive Phase 2 study results for their Lyme disease vaccine candidate, VLA15. The data shows consistent immune response and safety after a second booster dose.
The positive Phase 2 results for VLA15, showing consistent safety and immune response, are significant for Valneva. This supports the vaccine's potential for seasonal use, which could enhance Valneva's market position and lead to regulatory approvals.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80